PUBLISHED DATE : Sep 2022 | Pages : 357
Fill out your details & get your free sample
The Pharma R&D Outsourcing Market Size, Share, Growth Forecast by:
Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Share & Forecast 2022–2027
357 Pages
191 Tables
169 Charts
5 Regions
12 Countries
46 Companies
5 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2027) | USD 121.71 Billion |
| Market Size (2021) | USD 70.37 Billion |
| CAGR (2022-2027) | 9.56% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments | Stage of Development, Product Type, Company Size, Therapy Area, Geography |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| Countries Covered | US, Canada, Germany, France, UK, Italy, Spain, Japan, China, India, Australia, South Korea, Brazil, Mexico, Argentina, Turkey, Saudi Arabia, South Africa, and UAE |
The global pharma R&D outsourcing market was valued at USD 70.37 billion in 2021 and is expected to reach USD 121.71 billion by 2027, growing with a CAGR of 9.56% from 2022 to 2027. In a world of exponentially growing information, increasingly sophisticated technology, and an unstable economic environment, pharmaceutical corporations are increasingly outsourcing research efforts to academia and private contract research organizations (CROs). The pharmaceutical R&D outsourcing market is expected to grow as pharmaceutical and biotechnology companies spend more on outsourced services. Outsourced R&D activities span basic research through late-stage development, including genetic engineering, target identification, target validation, assay creation, hit discovery and lead optimization (hit candidates-as-a-service), safety and efficacy assessments in animal studies, and human clinical trials.
Paradigm Shift Towards Virtual Clinical Trials
The Emergence of Artificial intelligence (AI) in Drug Discovery & Development
Artificial intelligence (AI) is used in numerous areas across the world. In healthcare, especially in the pharmaceutical industry, AI is making a notable change as it has varied uses in drug discovery & development, clinical trials, and pharmaceutical productivity. The life cycle of a new drug from a lab to a store is a chain of many complex events that take time and development. Such difficult circumstances can be minimized with the help of AI, and the target can be achieved in a short time.
Many pharmaceutical companies implement innovative technologies such as AI and machine learning to achieve high-quality results in a short amount of time. In pharmaceutical product development, AI can manage the drug designing, decision making, and therapy determination for patients with personalized medicines; the generated clinical data can be stored for future drug development.
Global key players from the pharma and biotech industry, such as Eli Lilly Amgen, Merck, LEO, AstraZeneca, Bayer, Novartis, J&J, and BASF, are now a part of machine learning for pharmaceutical discovery.
Increasing Collaboration and partnership among CROs and Stakeholders of the Pharmaceutical Ecosystem
New models are emerging, and the first innovation comes from the Clinical Research Organization (CRO). CROs establish early chemical / biological entry points for the disease, approach potential interested companies, and collaborate on integrated drug discovery projects that they have identified. Strategic partnerships have long been an essential feature of the pharmaceutical industry. Numerous in-licenses, out-licenses, joint research, and joint development agreements exist between biopharmaceutical companies and academic research institutes.
In recent years, several significant outsourcing partnerships were done, such as the UK-based AstraZeneca partnering with academic organizations, the Cambridge University, focusing on drug development. It partnered with the University of Texas MD Anderson Cancer Center in the United States to develop immunotherapy.
Some of the examples of significant strategic partnerships of outsourcing are:
The pharma R&D outsourcing market is segmented on the product, stage of development, size of companies, therapy areas, and geography.
Insights by Product
Among all products, the small molecules segment reported a significant pharma R&D outsourcing market share. The small molecules segment is estimated to be higher because small molecules are likely to play a crucial part in easing the burden of chronic disease. This diverse group of small chemical compounds offers many benefits for scientists and researchers:
Pharmaceutical companies planning small molecule clinical studies need to work with the appropriate contract research organization (CRO) to conduct valuable research using reliable data. The food and Drug Administration (FDA) approved 50 novel drugs in 2021. 36 are small molecules which is 72% of the total approval of pharmaceutical drugs by the FDA.
Insights by Stage of development
Among stages of development, the clinical segment reported a major share of around 64.13% in 2021. The clinical segment is estimated to be higher because, according to World Health Organization (WHO), approximately 47,689 clinical trials are in Phase I. The high number of clinical trials in phase 1 is highly outsourced. In outsourcing well-established data about patient recruitment, activities of clinical trials related to phase 1 and other procedures such as analysis and documentation are the easy thing done in the phase.
Phase 1 clinical trials required more than USD 30 million in capital investment. Compounds in oncology, respiratory diseases, and other therapeutic areas require a lot of money. Around 70% of drugs move from Phase I to the next phase states by US FDA.
Phase II can last for several years; as per the WHO, around 88,530 compounds in phase 2 clinical trials till 2022. As per US FDA, approximately 33% of new drugs are moved from phase II to the next.
The number of subjects usually ranges from hundreds to about 3,000. If the FDA agrees that the study results are positive, the FDA will approve the experimental drug or equipment. As per the WHO, around 68,999 drugs came to phase III till 2022. In this phase, doctors, physicians, or professionals do not know whether the treatment is better, so random participants are picked up to get the approval for new treatment and sent into the next phase. This procedure is often done in many places across the region/world at the same time to analyze the efficacy of drugs in different geography and demography.
Insights by Size of Company
Among the size of the company, the small & mid-sized companies segment reported a major share of around 57.54% in 2021. The small & mid-sized companies market segment is estimated to be higher because, in 2019, the emerging therapeutic companies (ETC) were responsible for 73% (5,067 of 6,984) of global industrial, and pharmaceutical projects at all clinical stages, either alone or in collaboration with partners, with the rest being carried out by large companies.
SMEs will account for 71%, 76%, 68%, and 62% of Phase I, II, III, and new drug applications, respectively, compared to large companies. 45% of all clinical ETC pipeline projects are carried out in collaboration with other partners. Oncology is the main disease focus of these SME clinical projects.
In 2018, the Market researcher identified that 74 small pharmaceutical companies have total sales of $159 billion and 446 pharmaceuticals drugs in their R&D pipeline, 9 medium-sized companies with sales of $50 billion and 181 products, and sales of $139 billion in the R& D pipeline.
A 2017 BIO industry analysis shows that small biotechnology companies are responsible for 70% of all bio pharmacy clinical trials worldwide, representing 6,679 programs, 43% of which partner with other companies. It was carried out. Large companies conducted the remaining 30% of these clinical trials.
Insights by Therapy Areas
Among therapy areas, the oncology segment reported a major share of around 30.71% in 2021. The oncology segments are estimated to be higher because there are 19.3 million new cancer instances and approximately 10 million fatalities worldwide in 2020, accounting for nearly one out of every six deaths as per Globocan 2020 report.
Oncology is one of the most dominant therapy areas for industry and non-industry-sponsored clinical trials. The rising prevalence of cancer conditions significantly contributed to oncology therapeutic area clinical trials. Changing the paradigm for testing cancer treatment in the world increased the global efforts toward generating evidence for oncology clinical trials.
In 2019 only around 30 FDA approvals were registered for chemotherapeutic drugs. In the US, about 361,628 clinical trials have been reported only for cancer in the past 20 years. Cancer clinical trial drug development activities increased significantly, leading to increased clinical trial volume.
Global spending on anticancer medications climbed by 14.3% in 2020, reaching $164 billion. Spending is expected to reach $269 billion by 2025. The high prices of novel anticancer medicines drive much of this growth. The direct and indirect expenses of oncological treatments severely affect patients' treatment success and financial well-being worldwide.
In the US, around 361,628 clinical trials registered only for cancer in the past 20 years. Cancer clinical trial drug development activities increased significantly, leading to increased clinical trial volume.
The North America region reported a significant share of around 36.23% in 2021. The North America region is estimated to be higher because considerable investment by companies in R&D to strengthen the pipeline for chronic diseases is projected to boost the launch of novel therapeutics in North America. North America witnesses prominent start-up CROs working in the pharmaceutical R&D outsourcing market. The region also saw collaborations and partnerships among the pharmaceutical ecosystem's stakeholders.
Vendors in the pharma R&D outsourcing market compete based on the wide range of services offered, quality, and scale-up development of pharmaceuticals. The market is so competitive that vendors aim to implement different strategies to maintain their competitive advantage over other vendors. The market players focus on acquisitions, partnerships, diversifying their outsourcing services, and strengthening their distribution networks to increase their market share. There are around 33 vendors in the pharmaceutical R&D outsourcing market, including key players and other prominent players.
Frequently Asked Questions
How big is the pharmaceutical R&D outsourcing market?
The pharma R&D outsourcing market is expected to reach $121.71 billion by 2027.
What is the growth rate of the global pharmaceutical R&D outsourcing market?
The global pharma R&D outsourcing market is expected to grow at a CAGR of 9.56%.
Who are the key players in the global pharma R&D outsourcing market?
Labcorp Drug Development, Syneos Health, Charles River Laboratories, Thermo Fisher Scientific, ICON, IQVIA, Medpace, Lonza, Syneos Health are some of the key players in the global pharmaceutical R&D outsourcing market
Which geographical region leads in the pharma R&D outsourcing market?
The North America region has dominated the global pharmaceutical R&D outsourcing market.
What are the growth factors in the global pharmaceutical R&D outsourcing market?
Increasing collaboration and partnership among CROs and stakeholders of the pharmaceutical ecosystem and a surge in outsourcing of clinical trials are major growth factors in the global pharmaceutical R&D outsourcing market.
The Pharma R&D outsourcing market is expected to grow at a CAGR of approximately 9.56% from 2022 to 2027
The following factors are likely to contribute to the growth of the Pharmaceutical R&D outsourcing market during the forecast period:
Base Year: 2021
Forecast Year: 2022-2027
The report considers the present scenario of the Pharma R&D outsourcing market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Vendors
Other Prominent Vendors
Segmentation by Stage of Development
Segmentation by Product Type
Segmentation by Company Size
Segmentation by Therapy Area
Segmentation by Geography
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW
7.1.1 DRUG DEVELOPMENT
7.2 PHARMACEUTICALS AND THE NEED FOR OUTSOURCING R&D ACTIVITIES
7.2.1 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
8 PREMIUM INSIGHTS
8.1 MARKET OVERVIEW
8.1.1 PHARMACEUTICAL R&D OUTSOURCING MARKET SCENARIO
8.1.2 INSIGHT BY MARKET DYNAMICS
8.2 PHARMACEUTICAL R&D OUTSOURCING MARKET SEGMENTATIONS
8.2.1 INSIGHTS BY PRODUCT
8.2.2 INSIGHTS BY STAGE OF DEVELOPMENT
8.2.3 INSIGHTS BY COMPANY SIZE
8.2.4 INSIGHTS BY THERAPY AREA
8.2.5 INSIGHTS BY GEOGRAPHY
8.2.6 VENDOR LANDSCAPE
9 MARKET OPPORTUNITIES & TRENDS
9.1 PARADIGM SHIFT TOWARD VIRTUAL CLINICAL TRIALS
9.2 EMERGENCE OF AI IN DRUG DISCOVERY & DEVELOPMENT
9.3 RISING VENTURE CAPITALIST INVESTMENTS IN THE LIFE SCIENCES/BIOTECH INDUSTRY
9.4 SURGE IN USAGE OF CLOUD-BASED COMPUTING & RELATED SOFTWARE PLATFORMS IN R&D
10 MARKET GROWTH ENABLERS
10.1 INCREASING COLLABORATIONS AND PARTNERSHIPS AMONG CROS AND OTHER STAKEHOLDERS
10.2 INCREASING TARGET PATIENT DEMOGRAPHICS
10.3 SURGE IN OUTSOURCING OF CLINICAL TRIALS
11 MARKET RESTRAINTS
11.1 HIGH COST & LOW SUCCESS RATE OF PHARMACEUTICAL R&D
11.2 LACK OF TRANSPARENCY & SPECIFICITY, LONG TIMELINES, & CHANGING PRACTICES
11.3 GEOGRAPHICAL LOCATION AND CRUCIAL REGULATORY ASPECTS
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.2.1 INSIGHTS BY GEOGRAPHY
12.2.2 INSIGHTS BY STAGE OF DEVELOPMENT
12.2.3 INSIGHTS BY PRODUCT
12.2.4 INSIGHTS BY COMPANY SIZE
12.2.5 INSIGHTS BY THERAPY AREA
12.3 FIVE FORCES ANALYSIS
12.3.1 THREAT OF NEW ENTRANTS
12.3.2 BARGAINING POWER OF SUPPLIERS
12.3.3 BARGAINING POWER OF BUYERS
12.3.4 THREAT OF SUBSTITUTES
12.3.5 COMPETITIVE RIVALRY
13 STAGE OF DEVELOPMENT
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 CLINICAL
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 MARKET BY GEOGRAPHY
13.4 NON-CLINICAL
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 MARKET BY GEOGRAPHY
14 PRODUCT
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 SMALL MOLECULES
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 MARKET BY GEOGRAPHY
14.4 BIOLOGICS
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 MARKET BY GEOGRAPHY
15 COMPANY SIZE
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 SMALL & MID-SIZED COMPANIES
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 MARKET BY GEOGRAPHY
15.4 LARGE COMPANIES
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 MARKET BY GEOGRAPHY
16 THERAPY AREA
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 ONCOLOGY
16.3.1 MARKET OVERVIEW
16.3.2 MARKET SIZE & FORECAST
16.3.3 MARKET BY GEOGRAPHY
16.4 CARDIOVASCULAR DISEASES
16.4.1 MARKET OVERVIEW
16.4.2 MARKET SIZE & FORECAST
16.4.3 MARKET BY GEOGRAPHY
16.5 INFECTIOUS DISEASES
16.5.1 MARKET OVERVIEW
16.5.2 MARKET SIZE & FORECAST
16.5.3 MARKET BY GEOGRAPHY
16.6 MUSCULOSKELETAL DISORDERS
16.6.1 MARKET OVERVIEW
16.6.2 MARKET SIZE & FORECAST
16.6.3 MARKET BY GEOGRAPHY
16.7 CENTRAL NERVOUS SYSTEM DISORDERS
16.7.1 MARKET OVERVIEW
16.7.2 MARKET SIZE & FORECAST
16.7.3 MARKET BY GEOGRAPHY
16.8 GASTROINTESTINAL DISORDERS
16.8.1 MARKET OVERVIEW
16.8.2 MARKET SIZE & FORECAST
16.8.3 MARKET BY GEOGRAPHY
16.9 OTHER THERAPY AREAS
16.9.1 MARKET OVERVIEW
16.9.2 MARKET SIZE & FORECAST
16.9.3 MARKET BY GEOGRAPHY
17 GEOGRAPHY
17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 GEOGRAPHIC OVERVIEW
18 NORTH AMERICA
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.2.1 NORTH AMERICA: STAGE OF DEVELOPMENT
18.2.2 NORTH AMERICA: PRODUCT SEGMENTATION
18.2.3 NORTH AMERICA: COMPANY SIZE SEGMENTATION
18.2.4 NORTH AMERICA: THERAPY AREA SEGMENTATION
18.3 KEY COUNTRIES
18.3.1 US: MARKET SIZE & FORECAST
18.3.2 CANADA: MARKET SIZE & FORECAST
19 EUROPE
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.2.1 EUROPE: STAGE OF DEVELOPMENT
19.2.2 EUROPE: PRODUCT SEGMENTATION
19.2.3 EUROPE: COMPANY SIZE SEGMENTATION
19.2.4 EUROPE: THERAPY AREA SEGMENTATION
19.3 KEY COUNTRIES
19.3.1 GERMANY: MARKET SIZE & FORECAST
19.3.2 UK: MARKET SIZE & FORECAST
19.3.3 FRANCE: MARKET SIZE & FORECAST
19.3.4 SPAIN: MARKET SIZE & FORECAST
19.3.5 ITALY: MARKET SIZE & FORECAST
20 APAC
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.2.1 APAC: STAGE OF DEVELOPMENT
20.2.2 APAC: PRODUCT SEGMENTATION
20.2.3 APAC: COMPANY SIZE SEGMENTATION
20.2.4 APAC: THERAPY AREA SEGMENTATION
20.3 KEY COUNTRIES
20.3.1 CHINA: MARKET SIZE & FORECAST
20.3.2 JAPAN: MARKET SIZE & FORECAST
20.3.3 INDIA: MARKET SIZE & FORECAST
20.3.4 AUSTRALIA: MARKET SIZE & FORECAST
20.3.5 SOUTH KOREA: MARKET SIZE & FORECAST
21 LATIN AMERICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.2.1 LATIN AMERICA: STAGE OF DEVELOPMENT
21.2.2 LATIN AMERICA: PRODUCT SEGMENTATION
21.2.3 LATIN AMERICA: COMPANY SIZE SEGMENTATION
21.2.4 LATIN AMERICA: THERAPY AREA SEGMENTATION
21.3 KEY COUNTRIES
21.3.1 BRAZIL: MARKET SIZE & FORECAST
21.3.2 MEXICO: MARKET SIZE & FORECAST
21.3.3 ARGENTINA: MARKET SIZE & FORECAST
22 MIDDLE EAST & AFRICA
22.1 MARKET OVERVIEW
22.2 MARKET SIZE & FORECAST
22.2.1 MIDDLE EAST & AFRICA: STAGE OF DEVELOPMENT
22.2.2 MIDDLE EAST & AFRICA: PRODUCT SEGMENTATION
22.2.3 MIDDLE EAST & AFRICA: COMPANY SIZE SEGMENTATION
22.2.4 MIDDLE EAST & AFRICA: THERAPY AREA SEGMENTATION
22.3 KEY COUNTRIES
22.3.1 TURKEY: MARKET SIZE & FORECAST
22.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
22.3.3 SOUTH AFRICA: MARKET SIZE & FORECAST
22.3.4 UAE: MARKET SIZE & FORECAST
23 COMPETITIVE LANDSCAPE
23.1 COMPETITION OVERVIEW
23.2 MARKET SHARE ANALYSIS
24 KEY COMPANY PROFILES
24.1 CHARLES RIVER LABORATORIES
24.1.1 BUSINESS OVERVIEW
24.1.2 CHARLES RIVER LABORATORIES IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
24.1.3 SERVICE OFFERINGS
24.1.4 KEY STRATEGIES
24.1.5 KEY STRENGTHS
24.1.6 KEY OPPORTUNITIES
24.2 ICON
24.2.1 BUSINESS OVERVIEW
24.2.2 ICON IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
24.2.3 SERVICE OFFERINGS
24.2.4 KEY STRATEGIES
24.2.5 KEY STRENGTHS
24.2.6 KEY OPPORTUNITIES
24.3 IQVIA
24.3.1 BUSINESS OVERVIEW
24.3.2 IQVIA IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
24.3.3 SERVICE OFFERINGS
24.3.4 KEY STRATEGIES
24.3.5 KEY STRENGTHS
24.3.6 KEY OPPORTUNITIES
24.4 LABCORP DRUG DEVELOPMENT
24.4.1 BUSINESS OVERVIEW
24.4.2 LABCORP DRUG DEVELOPMENT IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
24.4.3 SERVICE OFFERINGS
24.4.4 KEY STRATEGIES
24.4.5 KEY STRENGTHS
24.4.6 KEY OPPORTUNITIES
24.5 MEDPACE
24.5.1 BUSINESS OVERVIEW
24.5.2 MEDPACE IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
24.5.3 SERVICE OFFERINGS
24.5.4 KEY STRATEGIES
24.5.5 KEY STRENGTHS
24.5.6 KEY OPPORTUNITIES
24.6 PAREXEL INTERNATIONAL CORPORATION
24.6.1 BUSINESS OVERVIEW
24.6.2 PAREXEL INTERNATIONAL IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
24.6.3 SERVICE OFFERINGS
24.6.4 KEY STRATEGIES
24.6.5 KEY STRENGTHS
24.6.6 KEY OPPORTUNITIES
24.7 SYNEOS HEALTH
24.7.1 BUSINESS OVERVIEW
24.7.2 SYNEOS HEALTH IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
24.7.3 SERVICE OFFERINGS
24.7.4 KEY STRATEGIES
24.7.5 KEY STRENGTHS
24.7.6 KEY OPPORTUNITIES
24.8 THERMO FISHER SCIENTIFIC
24.8.1 BUSINESS OVERVIEW
24.8.2 THERMO FISHER SCIENTIFIC IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
24.8.3 SERVICE OFFERINGS
24.8.4 KEY STRATEGIES
24.8.5 KEY STRENGTHS
24.8.6 KEY OPPORTUNITIES
24.9 WUXI APPTEC
24.9.1 BUSINESS OVERVIEW
24.9.2 WUXI APPTEC IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
24.9.3 SERVICE OFFERINGS
24.9.4 KEY STRATEGIES
24.9.5 KEY STRENGTHS
24.9.6 KEY OPPORTUNITIES
24.10 LONZA
24.10.1 BUSINESS OVERVIEW
24.10.2 LONZA IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
24.10.3 SERVICE OFFERINGS
24.10.4 KEY STRATEGIES
24.10.5 KEY STRENGTHS
24.10.6 KEY OPPORTUNITIES
24.11 BOEHRINGER INGELHEIM
24.11.1 BUSINESS OVERVIEW
24.11.2 BOEHRINGER INGELHEIM IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
24.11.3 SERVICE OFFERINGS
24.11.4 KEY STRATEGIES
24.11.5 KEY STRENGTHS
24.11.6 KEY OPPORTUNITIES
24.12 SAMSUNG BIOLOGICS
24.12.1 BUSINESS OVERVIEW
24.12.2 SAMSUNG BIOLOGICS IN THE PHARMACEUTICAL R&D OUTSOURCING MARKET
24.12.3 SERVICE OFFERINGS
24.12.4 KEY STRATEGIES
24.12.5 KEY STRENGTHS
24.12.6 KEY OPPORTUNITIES
25 OTHER PROMINENT VENDORS
25.1 ABBVIE
25.1.1 BUSINESS OVERVIEW
25.1.2 SERVICE OFFERINGS
25.2 ADVANCED CLINICAL
25.2.1 BUSINESS OVERVIEW
25.2.2 PRODUCT OFFERINGS
25.3 BIOANALYTIX
25.3.1 BUSINESS OVERVIEW
25.3.2 PRODUCT OFFERINGS
25.4 ASYMCHEM
25.4.1 BUSINESS OVERVIEW
25.4.2 SERVICE OFFERINGS
25.5 ALCAMI
25.5.1 BUSINESS OVERVIEW
25.5.2 SERVICE OFFERINGS
25.6 BAVARIAN NORDIC
25.6.1 BUSINESS OVERVIEW
25.6.2 SERVICE OFFERINGS
25.7 CATALENT
25.7.1 BUSINESS OVERVIEW
25.7.2 SERVICE OFFERINGS
25.8 CURIA GLOBAL
25.8.1 BUSINESS OVERVIEW
25.8.2 SERVICE OFFERINGS
25.9 CHEMPARTNER
25.9.1 BUSINESS OVERVIEW
25.9.2 SERVICE OFFERINGS
25.10 CMED
25.10.1 BUSINESS OVERVIEW
25.10.2 PRODUCT OFFERINGS
25.11 CRITERIUM
25.11.1 BUSINESS OVERVIEW
25.11.2 PRODUCT OFFERINGS
25.12 CROMOS PHARMA
25.12.1 BUSINESS OVERVIEW
25.12.2 PRODUCT OFFERINGS
25.13 EVOTEC
25.13.1 BUSINESS OVERVIEW
25.13.2 SERVICE OFFERINGS
25.14 JUBILANT HOLLISTERSTIER
25.14.1 BUSINESS OVERVIEW
25.14.2 SERVICE OFFERINGS
25.15 KBI BIOPHARMA
25.15.1 BUSINESS OVERVIEW
25.15.2 SERVICE OFFERINGS
25.16 KCR S.A.
25.16.1 BUSINESS OVERVIEW
25.16.2 PRODUCT OFFERINGS
25.17 KEMWELL BIOPHARMA
25.17.1 BUSINESS OVERVIEW
25.17.2 SERVICE OFFERINGS
25.18 MESNED PHARMA CONSULT CENTER (MPCC)
25.18.1 BUSINESS OVERVIEW
25.18.2 SERVICE OFFERINGS
25.19 MIDAS PHARMA
25.19.1 BUSINESS OVERVIEW
25.19.2 SERVICE OFFERINGS
25.20 MEDELIS
25.20.1 BUSINESS OVERVIEW
25.20.2 PRODUCT OFFERINGS
25.21 MERCK KGAA
25.21.1 BUSINESS OVERVIEW
25.21.2 SERVICE OFFERINGS
25.22 OCT CLINICAL
25.22.1 BUSINESS OVERVIEW
25.22.2 PRODUCT OFFERINGS
25.23 PHARMACEUTICS INTERNATIONAL
25.23.1 BUSINESS OVERVIEW
25.23.2 SERVICE OFFERINGS
25.24 PROTRIALS RESEARCH
25.24.1 BUSINESS OVERVIEW
25.24.2 PRODUCT OFFERINGS
25.25 PROMETRIKA
25.25.1 BUSINESS OVERVIEW
25.25.2 PRODUCT OFFERINGS
25.26 QPS
25.26.1 BUSINESS OVERVIEW
25.26.2 PRODUCT OFFERINGS
25.27 SINGOTA SOLUTIONS
25.27.1 BUSINESS OVERVIEW
25.27.2 SERVICE OFFERINGS
25.28 SOFPROMED
25.28.1 BUSINESS OVERVIEW
25.28.2 SERVICE OFFERINGS
25.29 SANOFI
25.29.1 BUSINESS OVERVIEW
25.29.2 SERVICE OFFERINGS
25.30 TAROS CHEMICALS
25.30.1 BUSINESS OVERVIEW
25.30.2 SERVICE OFFERINGS
25.31 VERISTAT
25.31.1 BUSINESS OVERVIEW
25.31.2 PRODUCT OFFERINGS
25.32 WORLDWIDE CLINICAL TRIALS
25.32.1 BUSINESS OVERVIEW
25.32.2 PRODUCT OFFERINGS
25.33 WUXI BIOLOGICS
25.33.1 BUSINESS OVERVIEW
25.33.2 SERVICE OFFERINGS
25.34 WACKER BIOTECH B.V
25.34.1 BUSINESS OVERVIEW
25.34.2 SERVICE OFFERINGS
26 REPORT SUMMARY
26.1 KEY TAKEAWAYS
26.2 STRATEGIC RECOMMENDATIONS
27 QUANTITATIVE SUMMARY
27.1 MARKET BY STAGE OF DEVELOPMENT
27.1.1 NORTH AMERICA: STAGE OF DEVELOPMENT SEGMENTATION
27.1.2 EUROPE: STAGE OF DEVELOPMENT SEGMENTATION
27.1.3 APAC: STAGE OF DEVELOPMENT SEGMENTATION
27.1.4 LATIN AMERICA: STAGE OF DEVELOPMENT SEGMENTATION
27.1.5 MIDDLE EAST & AFRICA: STAGE OF DEVELOPMENT SEGMENTATION
27.2 MARKET BY PRODUCT
27.2.1 NORTH AMERICA: PRODUCT SEGMENTATION
27.2.2 EUROPE: PRODUCT SEGMENTATION
27.2.3 APAC: PRODUCT SEGMENTATION
27.2.4 LATIN AMERICA: PRODUCT SEGMENTATION
27.2.5 MIDDLE EAST & AFRICA: PRODUCT SEGMENTATION
27.3 MARKET BY COMPANY SIZE
27.3.1 NORTH AMERICA: COMPANY SIZE SEGMENTATION
27.3.2 EUROPE: COMPANY SIZE SEGMENTATION
27.3.3 APAC: COMPANY SIZE SEGMENTATION
27.3.4 LATIN AMERICA: COMPANY SIZE SEGMENTATION
27.3.5 MIDDLE EAST & AFRICA: COMPANY SIZE SEGMENTATION
27.4 MARKET BY THERAPY AREA
27.4.1 NORTH AMERICA: THERAPY AREA SEGMENTATION
27.4.2 EUROPE: THERAPY AREA SEGMENTATION
27.4.3 APAC: THERAPY AREA SEGMENTATION
27.4.4 LATIN AMERICA: THERAPY AREA SEGMENTATION
27.4.5 MIDDLE EAST & AFRICA: THERAPY AREA SEGMENTATION
27.5 MARKET BY GEOGRAPHY
27.5.1 CLINICAL: GEOGRAPHY SEGMENTATION
27.5.2 NON-CLINICAL: GEOGRAPHY SEGMENTATION
27.5.3 SMALL MOLECULES: GEOGRAPHY SEGMENTATION
27.5.4 BIOLOGICS: GEOGRAPHY SEGMENTATION
27.5.5 SMALL & MID-SIZED COMPANIES: GEOGRAPHY SEGMENTATION
27.5.6 LARGE COMPANIES: GEOGRAPHY SEGMENTATION
27.5.7 ONCOLOGY: GEOGRAPHY SEGMENTATION
27.5.8 CARDIOVASCULAR DISEASES: GEOGRAPHY SEGMENTATION
27.5.9 INFECTIOUS DISEASES: GEOGRAPHY SEGMENTATION
27.5.10 MUSCULOSKELETAL DISORDERS: GEOGRAPHY SEGMENTATION
27.5.11 CENTRAL NERVOUS SYSTEM DISORDERS: GEOGRAPHY SEGMENTATION
27.5.12 GASTROINTESTINAL DISORDERS: GEOGRAPHY SEGMENTATION
27.5.13 OTHER THERAPY AREAS: GEOGRAPHY SEGMENTATION
28 APPENDIX
28.1 ABBREVIATIONS
EXHIBIT 1 SEGMENTATION OF GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 NUMBER OF DRUGS APPROVED IN THE US 2013-2018
EXHIBIT 4 PHARMA R&D EXPENDITURES IN THE US, EUROPE, & JAPAN 2000, 2010, 2018, & 2019 ($ BILLION)
EXHIBIT 5 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET ($ BILLION)
EXHIBIT 6 COLLABORATION OF CROS WITH OTHER STAKEHOLDERS OF THE PHARMACEUTICAL ECOSYSTEM
EXHIBIT 7 PHARMACEUTICAL R&D OUTSOURCING MARKET SEGMENTATIONS
EXHIBIT 8 PROBABILITY OF PHASE III SUCCESS 2010-2020
EXHIBIT 9 IMPACT OF PARADIGM SHIFT TOWARD VIRTUAL CLINICAL TRIALS
EXHIBIT 10 IMPACT OF EMERGENCE OF AI IN DRUG DISCOVERY & DEVELOPMENT
EXHIBIT 11 IMPACT OF RISING VENTURE CAPITALIST INVESTMENTS IN THE LIFE SCIENCES/BIOTECH INDUSTRY
EXHIBIT 12 IMPACT OF SURGE IN USAGE OF CLOUD-BASED COMPUTING & RELATED SOFTWARE PLATFORMS IN R&D
EXHIBIT 13 IMPACT OF INCREASING COLLABORATIONS AND PARTNERSHIPS AMONG CROS AND OTHER STAKEHOLDERS
EXHIBIT 14 COLLABORATION OF CROS WITH OTHER STAKEHOLDERS OF THE PHARMACEUTICAL ECOSYSTEM
EXHIBIT 15 COLLABORATION AND PARTNERSHIP AMONG STAKEHOLDERS OF THE PHARMACEUTICAL ECOSYSTEM
EXHIBIT 16 IMPACT OF INCREASING TARGET PATIENT DEMOGRAPHICS
EXHIBIT 17 NON-COMMUNICABLE DISEASES STATISTICS
EXHIBIT 18 AUTOIMMUNE DISEASES STATISTICS OF THE US
EXHIBIT 19 IMPACT OF SURGE IN OUTSOURCING OF CLINICAL TRIALS
EXHIBIT 20 IMPACT OF HIGH COST & LOW SUCCESS RATE OF PHARMACEUTICAL R&D
EXHIBIT 21 SUCCESS RATE OF DRUGS IN CLINICAL TRIALS
EXHIBIT 22 SUCCESS RATES AND COLLABORATIONS WITH PRIVATE COMPANIES
EXHIBIT 23 IMPACT OF LACK OF TRANSPARENCY & SPECIFICITY, LONG TIMELINES, & CHANGING PRACTICES
EXHIBIT 24 IMPACT OF GEOGRAPHICAL LOCATION AND CRUCIAL REGULATORY ASPECTS
EXHIBIT 25 CHALLENGES IN CLINICAL RESEARCH AND CLINICAL TRIALS
EXHIBIT 26 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET 2021–2027 ($ BILLION)
EXHIBIT 27 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY GEOGRAPHY
EXHIBIT 28 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT
EXHIBIT 29 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT
EXHIBIT 30 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE
EXHIBIT 31 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA
EXHIBIT 32 FIVE FORCES ANALYSIS 2021
EXHIBIT 33 INCREMENTAL GROWTH BY STAGE OF DEVELOPMENT 2021 & 2027
EXHIBIT 34 PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT
EXHIBIT 35 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT: INCREMENTAL GROWTH
EXHIBIT 36 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT: ABSOLUTE GROWTH
EXHIBIT 37 TOTAL NUMBER OF CLINICAL TRIALS BY PHASES IN 1999-2021
EXHIBIT 38 GLOBAL PHARMACEUTICAL R&D OUTSOURCING CLINICAL MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 39 PROBABILITY OF PHASE III SUCCESS 2010-2020
EXHIBIT 40 GLOBAL PHARMACEUTICAL R&D OUTSOURCING CLINICAL MARKET 2021–2027 ($ BILLION)
EXHIBIT 41 STAGES OF DRUG DISCOVERY AND PRECLINICAL DEVELOPMENT
EXHIBIT 42 RESEARCHERS DETERMINE THE FOLLOWING ABOUT THE DRUG:
EXHIBIT 43 GLOBAL PHARMACEUTICAL R&D OUTSOURCING NON-CLINICAL MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 44 GLOBAL PHARMACEUTICAL R&D OUTSOURCING NON-CLINICAL MARKET 2021–2027 ($ BILLION)
EXHIBIT 45 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 46 PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT
EXHIBIT 47 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT: INCREMENTAL GROWTH
EXHIBIT 48 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT: ABSOLUTE GROWTH
EXHIBIT 49 FDA APPROVED DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) – LAST SEVEN YEARS
EXHIBIT 50 GLOBAL PHARMACEUTICAL R&D OUTSOURCING SMALL MOLECULES MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 51 GLOBAL PHARMACEUTICAL R&D OUTSOURCING SMALL MOLECULES MARKET 2021–2027 ($ BILLION)
EXHIBIT 52 GLOBAL PHARMACEUTICAL R&D OUTSOURCING BIOLOGICS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 53 ROBUST PIPELINE VACCINE (2022)
EXHIBIT 54 GENE THERAPIES IN PIPELINE 2020 VS 2021
EXHIBIT 55 GLOBAL PHARMACEUTICAL R&D OUTSOURCING BIOLOGICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 56 INCREMENTAL GROWTH BY COMPANY SIZE 2021 & 2027
EXHIBIT 57 PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE
EXHIBIT 58 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE: INCREMENTAL GROWTH
EXHIBIT 59 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE: ABSOLUTE GROWTH
EXHIBIT 60 GLOBAL PHARMACEUTICAL R&D OUTSOURCING SMALL & MID-SIZED COMPANIES MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 61 GLOBAL PHARMACEUTICAL R&D OUTSOURCING SMALL & MID-SIZED COMPANIES MARKET 2021–2027 ($ BILLION)
EXHIBIT 62 GLOBAL PHARMACEUTICAL R&D OUTSOURCING LARGE COMPANIES MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 63 GLOBAL PHARMACEUTICAL R&D OUTSOURCING LARGE COMPANIES MARKET 2021–2027 ($ BILLION)
EXHIBIT 64 INCREMENTAL GROWTH BY THERAPY AREA 2021 & 2027
EXHIBIT 65 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA: INCREMENTAL GROWTH
EXHIBIT 66 MUSCULOSKELETAL DISORDERS STATISTICS
EXHIBIT 67 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA: ABSOLUTE GROWTH
EXHIBIT 68 GLOBAL PHARMACEUTICAL R&D OUTSOURCING ONCOLOGY MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 69 ONCOLOGY CLINICAL TRIALS BY PHASE 2020 (%)
EXHIBIT 70 GLOBAL PHARMACEUTICAL R&D OUTSOURCING ONCOLOGY MARKET 2021–2027 ($ BILLION)
EXHIBIT 71 GLOBAL PHARMACEUTICAL R&D OUTSOURCING CARDIOVASCULAR DISEASES MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 72 GLOBAL PHARMACEUTICAL R&D OUTSOURCING CARDIOVASCULAR DISEASES MARKET 2021–2027 ($ BILLION)
EXHIBIT 73 INFECTIOUS DISEASE STATISTICS WORLDWIDE
EXHIBIT 74 GLOBAL PHARMACEUTICAL R&D OUTSOURCING INFECTIOUS DISEASES MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 75 GLOBAL PHARMACEUTICAL R&D OUTSOURCING INFECTIOUS DISEASES MARKET 2021–2027 ($ BILLION)
EXHIBIT 76 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MUSCULOSKELETAL DISORDERS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 77 MUSCULOSKELETAL DISORDER – CLINICAL TRIALS
EXHIBIT 78 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MUSCULOSKELETAL DISORDERS MARKET 2021–2027 ($ BILLION)
EXHIBIT 79 CENTRAL NERVOUS SYSTEM DISORDER STATISTICS 2020
EXHIBIT 80 GLOBAL PHARMACEUTICAL R&D OUTSOURCING CENTRAL NERVOUS SYSTEM DISORDERS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 81 GLOBAL PHARMACEUTICAL R&D OUTSOURCING CENTRAL NERVOUS SYSTEM DISORDERS MARKET 2021–2027 ($ BILLION)
EXHIBIT 82 GLOBAL PHARMACEUTICAL R&D OUTSOURCING GASTROINTESTINAL DISORDERS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 83 GLOBAL PHARMACEUTICAL R&D OUTSOURCING GASTROINTESTINAL DISORDERS MARKET 2021–2027 ($ BILLION)
EXHIBIT 84 GLOBAL PHARMACEUTICAL R&D OUTSOURCING OTHER THERAPY AREAS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 85 GLOBAL PHARMACEUTICAL R&D OUTSOURCING OTHER THERAPY AREAS MARKET 2021–2027 ($ BILLION)
EXHIBIT 86 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 87 PHARMACEUTICAL R&D OUTSOURCING MARKET BY GEOGRAPHY
EXHIBIT 88 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET: KEY COUNTRIES
EXHIBIT 89 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
EXHIBIT 90 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
EXHIBIT 91 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET IN NORTH AMERICA: KEY COUNTRIES
EXHIBIT 92 PHARMACEUTICAL R&D OUTSOURCING MARKET IN NORTH AMERICA: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 93 PHARMACEUTICAL R&D OUTSOURCING MARKET IN NORTH AMERICA 2021–2027 ($ BILLION)
EXHIBIT 94 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
EXHIBIT 95 % OF REGISTERED STUDIES BY LOCATION (TOTAL 410,703) (AS OF APRIL 2022)
EXHIBIT 96 PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE US 2021–2027 ($ BILLION)
EXHIBIT 97 TOTAL CANADIAN PHARMACEUTICAL BUSINESS R&D EXPENDITURES (2011–2019)
EXHIBIT 98 PHARMACEUTICAL R&D OUTSOURCING MARKET IN CANADA 2021–2027 ($ BILLION)
EXHIBIT 99 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET IN EUROPE: KEY COUNTRIES
EXHIBIT 100 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET IN EUROPE: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 101 PHARMACEUTICAL R&D OUTSOURCING MARKET IN EUROPE 2021–2027 ($ BILLION)
EXHIBIT 102 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
EXHIBIT 103 INDUSTRY-SPONSORED TOP THERAPY AREAS FOR CLINICAL TRIALS IN GERMANY 2020 (%)
EXHIBIT 104 PHARMACEUTICAL R&D OUTSOURCING MARKET IN GERMANY 2021–2027 ($ BILLION)
EXHIBIT 105 PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE UK 2021–2027 ($ BILLION)
EXHIBIT 106 FRANCE: TOP THERAPY AREAS OF INDUSTRY-SPONSORED CLINICAL TRIALS 2020 (%)
EXHIBIT 107 PHARMACEUTICAL R&D OUTSOURCING MARKET IN FRANCE 2021–2027 ($ BILLION)
EXHIBIT 108 FACTORS ATTRACTING GLOBAL SPONSORS FOR CLINICAL TRIALS
EXHIBIT 109 PHARMACEUTICAL R&D OUTSOURCING MARKET IN SPAIN 2021–2027 ($ BILLION)
EXHIBIT 110 TOP THERAPY AREAS OF INDUSTRY-SPONSORED CLINICAL TRIALS
EXHIBIT 111 PHARMACEUTICAL R&D OUTSOURCING MARKET IN ITALY 2021–2027 ($ BILLION)
EXHIBIT 112 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET IN APAC: KEY COUNTRIES
EXHIBIT 113 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET IN APAC: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 114 PHARMACEUTICAL R&D OUTSOURCING MARKET IN APAC 2021–2027 ($ BILLION)
EXHIBIT 115 INCREMENTAL GROWTH IN APAC 2021 & 2027
EXHIBIT 116 CHINA CLINICAL TRIALS 2012-2021 (TEN YEAR TREND)
EXHIBIT 117 PHARMACEUTICAL R&D OUTSOURCING MARKET IN CHINA 2021–2027 ($ BILLION)
EXHIBIT 118 PHARMACEUTICAL R&D OUTSOURCING MARKET IN JAPAN 2021–2027 ($ BILLION)
EXHIBIT 119 PHARMACEUTICAL R&D OUTSOURCING MARKET IN INDIA 2021–2027 ($ BILLION)
EXHIBIT 120 PHARMACEUTICAL R&D OUTSOURCING MARKET IN AUSTRALIA 2021–2027 ($ BILLION)
EXHIBIT 121 INDUSTRY SPONSORED & NON-INDUSTRY SPONSORED TRIALS IN SOUTH KOREA (2011–2020)
EXHIBIT 122 PHARMACEUTICAL R&D OUTSOURCING MARKET IN SOUTH KOREA 2021–2027 ($ BILLION)
EXHIBIT 123 PHARMACEUTICAL R&D OUTSOURCING MARKET IN LATIN AMERICA: KEY COUNTRIES
EXHIBIT 124 PHARMACEUTICAL R&D OUTSOURCING MARKET IN LATIN AMERICA: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 125 PHARMACEUTICAL R&D OUTSOURCING MARKET IN LATIN AMERICA 2021–2027 ($ BILLION)
EXHIBIT 126 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
EXHIBIT 127 PHARMACEUTICAL R&D OUTSOURCING MARKET IN BRAZIL 2021–2027 ($ BILLION)
EXHIBIT 128 PHARMACEUTICAL R&D OUTSOURCING MARKET IN MEXICO 2021–2027 ($ BILLION)
EXHIBIT 129 PHARMACEUTICAL R&D OUTSOURCING MARKET IN ARGENTINA 2021–2027 ($ BILLION)
EXHIBIT 130 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE MIDDLE EAST & AFRICA: KEY COUNTRIES
EXHIBIT 131 PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE MIDDLE EAST & AFRICA: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 132 PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE MIDDLE EAST & AFRICA 2021–2027 ($ BILLION)
EXHIBIT 133 INCREMENTAL GROWTH IN THE MIDDLE EAST & AFRICA 2021 & 2027
EXHIBIT 134 PHARMACEUTICAL R&D OUTSOURCING MARKET IN TURKEY 2021–2027 ($ BILLION)
EXHIBIT 135 PHARMACEUTICAL R&D OUTSOURCING MARKET IN SAUDI ARABIA 2021–2027 ($ BILLION)
EXHIBIT 136 PHARMACEUTICAL R&D OUTSOURCING MARKET IN SOUTH AFRICA 2021–2027 ($ BILLION)
EXHIBIT 137 PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE UAE 2021–2027 ($ BILLION)
EXHIBIT 138 PHARMACEUTICAL R&D OUTSOURCING MARKET CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 139 PHARMACEUTICAL R&D OUTSOURCING MARKET CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 140 CHARLES RIVER LABORATORIES: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 141 CHARLES RIVER LABORATORIES: REVENUE BY BUSINESS SEGMENTS 2021 (%)
EXHIBIT 142 CHARLES RIVER LABORATORIES: REVENUE BY GEOGRAPHY 2021 (%)
EXHIBIT 143 CHARLES RIVER LABORATORIES: REVENUE BY CLIENT SEGMENT 2021
EXHIBIT 144 ICON: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 145 ICON: REVENUE BY GEOGRAPHY 2020 (%)
EXHIBIT 146 IQVIA: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 147 IQVIA: RESEARCH & DEVELOPMENT EXPENDITURE ($ MILLION)
EXHIBIT 148 LABCORP DRUG DEVELOPMENT: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 149 LABCORP DRUG DEVELOPMENT: REVENUE BY BUSINESS SEGMENTS 2021 (%)
EXHIBIT 150 LABCORP DRUG DEVELOPMENT: REVENUE BY GEOGRAPHY 2021 (%)
EXHIBIT 151 MEDPACE: TOTAL REVENUE 2018–2020 ($ MILLION)
EXHIBIT 152 MEDPACE: REVENUE SHARE BY CATEGORY (%)
EXHIBIT 153 SYNEOS HEALTH: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 154 SYNEOS HEALTH: REVENUE SHARE BY BUSINESS SEGMENT 2021 (%)
EXHIBIT 155 SYNEOS HEALTH: REVENUE BY GEOGRAPHY 2021 (%)
EXHIBIT 156 THERMO FISHER SCIENTIFIC: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 157 THERMO FISHER SCIENTIFIC: REVENUE BY BUSINESS SEGMENT 2021 (%)
EXHIBIT 158 THERMO FISHER SCIENTIFIC: REVENUE BY GEOGRAPHY 2021 (%)
EXHIBIT 159 WUXI APPTEC: TOTAL REVENUE 2019–2021 ($ BILLION)
EXHIBIT 160 WUXI APPTEC: REVENUE BY GEOGRAPHY 2021 (%)
EXHIBIT 161 LONZA: TOTAL SALES 2019–2021 ($ MILLION)
EXHIBIT 162 LONZA: REVENUE BY GEOGRAPHY 2021 (%)
EXHIBIT 163 LONZA: REVENUE BY REPORTABLE DIVISIONS (%)
EXHIBIT 164 BOEHRINGER INGELHEIM: TOTAL REVENUE 2019–2021 ($ BILLION)
EXHIBIT 165 BOEHRINGER INGELHEIM: REVENUE BY BUSINESS UNIT (%)
EXHIBIT 166 BOEHRINGER INGELHEIM: REVENUE BY GEOGRAPHY 2021 (%)
EXHIBIT 167 SAMSUNG BIOLOGICS: TOTAL SALES 2019–2021 ($ MILLION)
EXHIBIT 168 SAMSUNG BIOLOGICS: REVENUE BY PRODUCT TYPE 2021 (%)
EXHIBIT 169 SAMSUNG BIOLOGICS: REVENUE BY GEOGRAPHY 2021 (%)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 PHARMACEUTICAL R&D OUTSOURCING CLINICAL MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 4 PHARMACEUTICAL R&D OUTSOURCING CLINICAL MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 5 PHARMACEUTICAL R&D OUTSOURCING NON-CLINICAL MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 6 PHARMACEUTICAL R&D OUTSOURCING NON-CLINICAL MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 7 PHARMACEUTICAL R&D OUTSOURCING SMALL MOLECULES MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 8 PHARMACEUTICAL R&D OUTSOURCING SMALL MOLECULES MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 9 NUMBER OF PIPELINE VACCINE CANDIDATES
TABLE 10 PHARMACEUTICAL R&D OUTSOURCING BIOLOGICS MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 11 PHARMACEUTICAL R&D OUTSOURCING BIOLOGICS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 12 PHARMACEUTICAL R&D OUTSOURCING SMALL & MID-SIZED COMPANIES MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 13 PHARMACEUTICAL R&D OUTSOURCING SMALL & MID-SIZED COMPANIES MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 14 PHARMACEUTICAL R&D OUTSOURCING LARGE COMPANIES MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 15 PHARMACEUTICAL R&D OUTSOURCING LARGE COMPANIES MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 16 PHARMACEUTICAL R&D OUTSOURCING ONCOLOGY MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 17 PHARMACEUTICAL R&D OUTSOURCING ONCOLOGY MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 18 PHARMACEUTICAL R&D OUTSOURCING CARDIOVASCULAR DISEASES MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 19 PHARMACEUTICAL R&D OUTSOURCING CARDIOVASCULAR DISEASES MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 20 PHARMACEUTICAL R&D OUTSOURCING INFECTIOUS DISEASES MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 21 PHARMACEUTICAL R&D OUTSOURCING INFECTIOUS DISEASES MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 22 PHARMACEUTICAL R&D OUTSOURCING MUSCULOSKELETAL DISORDERS MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 23 PHARMACEUTICAL R&D OUTSOURCING MUSCULOSKELETAL DISORDERS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 24 PHARMACEUTICAL R&D OUTSOURCING CENTRAL NERVOUS SYSTEM DISORDERS MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 25 PHARMACEUTICAL R&D OUTSOURCING CENTRAL NERVOUS SYSTEM DISORDERS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 26 PHARMACEUTICAL R&D OUTSOURCING GASTROINTESTINAL DISORDERS MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 27 PHARMACEUTICAL R&D OUTSOURCING GASTROINTESTINAL DISORDERS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 28 PHARMACEUTICAL R&D OUTSOURCING OTHER THERAPY AREAS MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 29 PHARMACEUTICAL R&D OUTSOURCING OTHER THERAPY AREAS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 30 PHARMACEUTICAL R&D OUTSOURCING MARKET IN NORTH AMERICA BY STAGE OF DEVELOPMENT 2021−2027 ($ BILLION)
TABLE 31 PHARMACEUTICAL R&D OUTSOURCING MARKET IN NORTH AMERICA BY STAGE OF DEVELOPMENT 2021−2027 (%)
TABLE 32 PHARMACEUTICAL R&D OUTSOURCING MARKET IN NORTH AMERICA BY PRODUCT 2021−2027 ($ BILLION)
TABLE 33 PHARMACEUTICAL R&D OUTSOURCING MARKET IN NORTH AMERICA BY PRODUCT 2021−2027 (%)
TABLE 34 PHARMACEUTICAL R&D OUTSOURCING MARKET IN NORTH AMERICA BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 35 PHARMACEUTICAL R&D OUTSOURCING MARKET IN NORTH AMERICA BY COMPANY SIZE 2021−2027 (%)
TABLE 36 PHARMACEUTICAL R&D OUTSOURCING MARKET IN NORTH AMERICA BY THERAPY AREA 2021−2027 ($ BILLION)
TABLE 37 PHARMACEUTICAL R&D OUTSOURCING MARKET IN NORTH AMERICA BY THERAPY AREA 2021−2027 (%)
TABLE 38 PHARMACEUTICAL R&D OUTSOURCING MARKET IN EUROPE BY STAGE OF DEVELOPMENT 2021−2027 ($ BILLION)
TABLE 39 PHARMACEUTICAL R&D OUTSOURCING MARKET IN EUROPE BY STAGE OF DEVELOPMENT 2021−2027 (%)
TABLE 40 PHARMACEUTICAL R&D OUTSOURCING MARKET IN EUROPE BY PRODUCT 2021−2027 ($ BILLION)
TABLE 41 PHARMACEUTICAL R&D OUTSOURCING MARKET IN EUROPE BY PRODUCT 2021−2027 (%)
TABLE 42 PHARMACEUTICAL R&D OUTSOURCING MARKET IN EUROPE BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 43 PHARMACEUTICAL R&D OUTSOURCING MARKET IN EUROPE BY COMPANY SIZE 2021−2027 (%)
TABLE 44 PHARMACEUTICAL R&D OUTSOURCING MARKET IN EUROPE BY THERAPY AREA 2021−2027 ($ BILLION)
TABLE 45 PHARMACEUTICAL R&D OUTSOURCING MARKET IN EUROPE BY THERAPY AREA 2021−2027 (%)
TABLE 46 PHARMACEUTICAL R&D OUTSOURCING MARKET IN APAC BY STAGE OF DEVELOPMENT 2021−2027 ($ BILLION)
TABLE 47 PHARMACEUTICAL R&D OUTSOURCING MARKET IN APAC BY STAGE OF DEVELOPMENT 2021−2027 (%)
TABLE 48 PHARMACEUTICAL R&D OUTSOURCING MARKET IN APAC BY PRODUCT 2021−2027 ($ BILLION)
TABLE 49 PHARMACEUTICAL R&D OUTSOURCING MARKET IN APAC BY PRODUCT 2021−2027 (%)
TABLE 50 PHARMACEUTICAL R&D OUTSOURCING MARKET IN APAC BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 51 PHARMACEUTICAL R&D OUTSOURCING MARKET IN APAC BY COMPANY SIZE 2021−2027 (%)
TABLE 52 PHARMACEUTICAL R&D OUTSOURCING MARKET IN APAC BY THERAPY AREA 2021−2027 ($ BILLION)
TABLE 53 PHARMACEUTICAL R&D OUTSOURCING MARKET IN APAC BY THERAPY AREA 2021−2027 (%)
TABLE 54 PHARMACEUTICAL R&D OUTSOURCING MARKET IN LATIN AMERICA BY STAGE OF DEVELOPMENT 2021−2027 ($ BILLION)
TABLE 55 PHARMACEUTICAL R&D OUTSOURCING MARKET IN LATIN AMERICA BY STAGE OF DEVELOPMENT 2021−2027 (%)
TABLE 56 PHARMACEUTICAL R&D OUTSOURCING MARKET IN LATIN AMERICA BY PRODUCT 2021−2027 ($ BILLION)
TABLE 57 PHARMACEUTICAL R&D OUTSOURCING MARKET IN LATIN AMERICA BY PRODUCT 2021−2027 (%)
TABLE 58 PHARMACEUTICAL R&D OUTSOURCING MARKET IN LATIN AMERICA BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 59 PHARMACEUTICAL R&D OUTSOURCING MARKET IN LATIN AMERICA BY COMPANY SIZE 2021−2027 (%)
TABLE 60 PHARMACEUTICAL R&D OUTSOURCING MARKET IN LATIN AMERICA BY THERAPY AREA 2021−2027 ($ BILLION)
TABLE 61 PHARMACEUTICAL R&D OUTSOURCING MARKET IN LATIN AMERICA BY THERAPY AREA 2021−2027 (%)
TABLE 62 PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE MIDDLE EAST & AFRICA BY STAGE OF DEVELOPMENT 2021−2027 ($ BILLION)
TABLE 63 PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE MIDDLE EAST & AFRICA BY STAGE OF DEVELOPMENT 2021−2027 (%)
TABLE 64 PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE MIDDLE EAST & AFRICA BY PRODUCT 2021−2027 ($ BILLION)
TABLE 65 PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE MIDDLE EAST & AFRICA BY PRODUCT 2021−2027 (%)
TABLE 66 PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE MIDDLE EAST & AFRICA BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 67 PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE MIDDLE EAST & AFRICA BY COMPANY SIZE 2021−2027 (%)
TABLE 68 PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE MIDDLE EAST & AFRICA BY THERAPY AREA 2021−2027 ($ BILLION)
TABLE 69 PHARMACEUTICAL R&D OUTSOURCING MARKET IN THE MIDDLE EAST & AFRICA BY THERAPY AREA 2021−2027 (%)
TABLE 70 CHARLES RIVER LABORATORIES: MAJOR SERVICE OFFERINGS
TABLE 71 ICON: MAJOR SERVICE OFFERINGS
TABLE 72 IQVIA: MAJOR SERVICE OFFERINGS
TABLE 73 LABCORP DRUG DEVELOPMENT: MAJOR SERVICE OFFERINGS
TABLE 74 MEDPACE: MAJOR SERVICE OFFERINGS
TABLE 75 PAREXEL INTERNATIONAL: MAJOR SERVICE OFFERINGS
TABLE 76 SYNEOS HEALTH: MAJOR SERVICE OFFERINGS
TABLE 77 THERMO FISHER SCIENTIFIC: MAJOR SERVICE OFFERINGS
TABLE 78 WUXI APPTEC: MAJOR SERVICE OFFERINGS
TABLE 79 LONZA: MAJOR SERVICE OFFERINGS
TABLE 80 BOEHRINGER INGELHEIM: MAJOR SERVICE OFFERINGS
TABLE 81 SAMSUNG BIOLOGICS: MAJOR SERVICE OFFERINGS
TABLE 82 ABBVIE: MAJOR SERVICE OFFERINGS
TABLE 83 ADVANCED MEDICAL: MAJOR PRODUCT OFFERINGS
TABLE 84 BIOANALYTIX: MAJOR PRODUCT OFFERINGS
TABLE 85 ASYMCHEM: MAJOR SERVICE OFFERINGS
TABLE 86 ALCAMI: MAJOR SERVICE OFFERINGS
TABLE 87 BAVARIAN NORDIC: MAJOR SERVICE OFFERINGS
TABLE 88 CATALENT: MAJOR SERVICE OFFERINGS
TABLE 89 CURIA GLOBAL: MAJOR SERVICE OFFERINGS
TABLE 90 CHEMPARTNER: MAJOR SERVICE OFFERINGS
TABLE 91 CMED: MAJOR PRODUCT OFFERINGS
TABLE 92 CRITERIUM: MAJOR PRODUCT OFFERINGS
TABLE 93 CROMOS PHARMA: MAJOR PRODUCT OFFERINGS
TABLE 94 EVOTEC: MAJOR SERVICE OFFERINGS
TABLE 95 JUBILANT HOLLISTERSTIER: MAJOR SERVICE OFFERINGS
TABLE 96 KBI BIOPHARMA: MAJOR SERVICE OFFERINGS
TABLE 97 KCR: MAJOR PRODUCT OFFERINGS
TABLE 98 KEMWELL BIOPHARMA: MAJOR SERVICE OFFERINGS
TABLE 99 MESNED PHARMA CONSULT CENTER: MAJOR SERVICE OFFERINGS
TABLE 100 MIDAS PHARMA: MAJOR SERVICE OFFERINGS
TABLE 101 MEDELIS: MAJOR PRODUCT OFFERINGS
TABLE 102 MERCK: MAJOR SERVICE OFFERINGS
TABLE 103 OCT CLINICAL: MAJOR PRODUCT OFFERINGS
TABLE 104 PHARMACEUTICS INTERNATIONAL: MAJOR SERVICE OFFERINGS
TABLE 105 PROTRIALS RESEARCH: MAJOR PRODUCT OFFERINGS
TABLE 106 PROMETRIKA: MAJOR PRODUCT OFFERINGS
TABLE 107 QPS: MAJOR PRODUCT OFFERINGS
TABLE 108 SINGOTA SOLUTIONS: MAJOR SERVICE OFFERINGS
TABLE 109 SOFPROMED: MAJOR SERVICE OFFERINGS
TABLE 110 SANOFI: MAJOR SERVICE OFFERINGS
TABLE 111 TAROS CHEMICALS: MAJOR SERVICE OFFERINGS
TABLE 112 VERISTAT: MAJOR PRODUCT OFFERINGS
TABLE 113 WORLDWIDE CLINICAL TRIALS: MAJOR PRODUCT OFFERINGS
TABLE 114 WUXI BIOLOGICS: MAJOR SERVICE OFFERINGS
TABLE 115 WACKER BIOTECH: MAJOR SERVICE OFFERINGS
TABLE 116 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 ($ BILLION)
TABLE 117 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 (%)
TABLE 118 NORTH AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 ($ BILLION)
TABLE 119 NORTH AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 (%)
TABLE 120 EUROPE PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 ($ BILLION)
TABLE 121 EUROPE PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 (%)
TABLE 122 APAC PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 ($ BILLION)
TABLE 123 APAC PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 (%)
TABLE 124 LATIN AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 ($ BILLION)
TABLE 125 LATIN AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 (%)
TABLE 126 MIDDLE EAST & AFRICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 ($ BILLION)
TABLE 127 MIDDLE EAST & AFRICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 (%)
TABLE 128 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 ($ BILLION)
TABLE 129 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY STAGE OF DEVELOPMENT 2021−2027 (%)
TABLE 130 NORTH AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT 2021−2027 ($ BILLION)
TABLE 131 NORTH AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT 2021−2027 (%)
TABLE 132 EUROPE PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT 2021−2027 ($ BILLION)
TABLE 133 EUROPE PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT 2021−2027 (%)
TABLE 134 APAC PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT 2021−2027 ($ BILLION)
TABLE 135 APAC PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT 2021−2027 (%)
TABLE 136 LATIN AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT 2021−2027 ($ BILLION)
TABLE 137 LATIN AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT 2021−2027 (%)
TABLE 138 MIDDLE EAST & AFRICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT 2021−2027 ($ BILLION)
TABLE 139 MIDDLE EAST & AFRICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY PRODUCT 2021−2027 (%)
TABLE 140 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 141 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE 2021−2027 (%)
TABLE 142 NORTH AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 143 NORTH AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE 2021−2027 (%)
TABLE 144 EUROPE PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 145 EUROPE PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE 2021−2027 (%)
TABLE 146 APAC PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 147 APAC PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE 2021−2027 (%)
TABLE 148 LATIN AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 149 LATIN AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE 2021−2027 (%)
TABLE 150 MIDDLE EAST & AFRICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE 2021−2027 ($ BILLION)
TABLE 151 MIDDLE EAST & AFRICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY COMPANY SIZE 2021−2027 (%)
TABLE 152 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA 2021−2027 ($ BILLION)
TABLE 153 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA 2021–2027 (%)
TABLE 154 NORTH AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA 2021−2027 ($ BILLION)
TABLE 155 NORTH AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA 2021–2027 (%)
TABLE 156 EUROPE PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA 2021−2027 ($ BILLION)
TABLE 157 EUROPE PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA 2021–2027 (%)
TABLE 158 APAC PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA 2021−2027 ($ BILLION)
TABLE 159 APAC PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA 2021–2027 (%)
TABLE 160 LATIN AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA 2021−2027 ($ BILLION)
TABLE 161 LATIN AMERICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA 2021–2027 (%)
TABLE 162 MIDDLE EAST & AFRICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA 2021−2027 ($ BILLION)
TABLE 163 MIDDLE EAST & AFRICA PHARMACEUTICAL R&D OUTSOURCING MARKET BY THERAPY AREA 2021–2027 (%)
TABLE 164 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY GEOGRAPHY 2021−2027 ($ BILLION)
TABLE 165 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 166 GLOBAL PHARMACEUTICAL R&D OUTSOURCING CLINICAL MARKET 2021−2027 ($ BILLION)
TABLE 167 GLOBAL PHARMACEUTICAL R&D OUTSOURCING CLINICAL MARKET 2021−2027 (%)
TABLE 168 GLOBAL PHARMACEUTICAL R&D OUTSOURCING NON-CLINICAL MARKET 2021−2027 ($ BILLION)
TABLE 169 GLOBAL PHARMACEUTICAL R&D OUTSOURCING NON-CLINICAL MARKET 2021−2027 (%)
TABLE 170 GLOBAL PHARMACEUTICAL R&D OUTSOURCING SMALL MOLECULES MARKET 2021−2027 ($ BILLION)
TABLE 171 GLOBAL PHARMACEUTICAL R&D OUTSOURCING SMALL MOLECULES MARKET 2021−2027 (%)
TABLE 172 GLOBAL PHARMACEUTICAL R&D OUTSOURCING BIOLOGICS MARKET 2021−2027 ($ BILLION)
TABLE 173 GLOBAL PHARMACEUTICAL R&D OUTSOURCING BIOLOGICS MARKET 2021−2027 (%)
TABLE 174 GLOBAL PHARMACEUTICAL R&D OUTSOURCING SMALL & MID-SIZED COMPANIES MARKET 2021−2027 ($ BILLION)
TABLE 175 GLOBAL PHARMACEUTICAL R&D OUTSOURCING SMALL & MID-SIZED COMPANIES MARKET 2021−2027 (%)
TABLE 176 GLOBAL PHARMACEUTICAL R&D OUTSOURCING LARGE COMPANIES MARKET 2021−2027 ($ BILLION)
TABLE 177 GLOBAL PHARMACEUTICAL R&D OUTSOURCING LARGE COMPANIES MARKET 2021−2027 (%)
TABLE 178 GLOBAL PHARMACEUTICAL R&D OUTSOURCING ONCOLOGY MARKET 2021−2027 ($ BILLION)
TABLE 179 GLOBAL PHARMACEUTICAL R&D OUTSOURCING ONCOLOGY MARKET 2021−2027 (%)
TABLE 180 GLOBAL PHARMACEUTICAL R&D OUTSOURCING CARDIOVASCULAR DISEASES MARKET 2021−2027 ($ BILLION)
TABLE 181 GLOBAL PHARMACEUTICAL R&D OUTSOURCING CARDIOVASCULAR DISEASES MARKET 2021−2027 (%)
TABLE 182 GLOBAL PHARMACEUTICAL R&D OUTSOURCING INFECTIOUS DISEASES MARKET 2021−2027 ($ BILLION)
TABLE 183 GLOBAL PHARMACEUTICAL R&D OUTSOURCING INFECTIOUS DISEASES MARKET 2021−2027 (%)
TABLE 184 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MUSCULOSKELETAL DISORDERS MARKET 2021−2027 ($ BILLION)
TABLE 185 GLOBAL PHARMACEUTICAL R&D OUTSOURCING MUSCULOSKELETAL DISORDERS MARKET 2021−2027 (%)
TABLE 186 GLOBAL PHARMACEUTICAL R&D OUTSOURCING CENTRAL NERVOUS SYSTEM DISORDERS MARKET 2021−2027 ($ BILLION)
TABLE 187 GLOBAL PHARMACEUTICAL R&D OUTSOURCING CENTRAL NERVOUS SYSTEM DISORDERS MARKET 2021−2027 (%)
TABLE 188 GLOBAL PHARMACEUTICAL R&D OUTSOURCING GASTROINTESTINAL DISORDERS MARKET 2021−2027 ($ BILLION)
TABLE 189 GLOBAL PHARMACEUTICAL R&D OUTSOURCING GASTROINTESTINAL DISORDERS MARKET 2021−2027 (%)
TABLE 190 GLOBAL PHARMACEUTICAL R&D OUTSOURCING OTHER THERAPY AREAS MARKET 2021−2027 ($ BILLION)
TABLE 191 GLOBAL PHARMACEUTICAL R&D OUTSOURCING OTHER THERAPY AREAS MARKET 2021−2027 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
